Colby Pharmaceutical Overview
- Year Founded
-
2004
- Status
-
Private
- Employees
-
4
- Latest Deal Type
-
2ndary - Private
- Investors
-
1
Colby Pharmaceutical General Information
Description
Developer of pharmaceuticals targeting molecular pathways designed to treat neurodegeneration, inflammation, infectious disease, cancer, and allergy. The company develops oral small-molecule signal transduction modulator drugs and immune modulator biopharmaceuticals for cancer, chronic inflammation, pain, and infectious diseases, enabling patients to receive cures for hard-to-treat infections, inflammation, malignancies and pain with minimal toxicities and side effects.
Contact Information
Website
www.colbypharmaceuticals.comCorporate Office
- 24 Norman Way
- Suite A
- Belvedere Tiburon, CA 94920
- United States
Corporate Office
- 24 Norman Way
- Suite A
- Belvedere Tiburon, CA 94920
- United States
Colby Pharmaceutical Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Secondary Transaction - Private | Completed | Clinical Trials - Phase 3 | ||||
| 3. Later Stage VC | 01-Mar-2021 | Completed | Clinical Trials - Phase 3 | |||
| 2. Grant | 01-Jan-2014 | $1.75M | Completed | Clinical Trials - Phase 3 | ||
| 1. Grant | 24-Sep-2012 | $410K | Completed | Clinical Trials - Phase 3 |
Colby Pharmaceutical Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Colby Pharmaceutical Patents
Colby Pharmaceutical Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2011239432-A1 | Androgen induced oxidative stress inhibitors | Inactive | 16-Apr-2010 | ||
| CA-2796070-A1 | Androgen induced oxidative stress inhibitors | Inactive | 16-Apr-2010 | ||
| EP-2558454-A2 | Androgen induced oxidative stress inhibitors | Inactive | 16-Apr-2010 | ||
| EP-2558454-A4 | Androgen induced oxidative stress inhibitors | Inactive | 16-Apr-2010 | ||
| US-20130210772-A1 | Androgen induced oxidative stress inhibitors | Active | 16-Apr-2010 | C07D311/42 |
Colby Pharmaceutical Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Colby Pharmaceutical Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| U.S. Department of Health and Human Services | Government |
Colby Pharmaceutical Investments & Acquisitions (3)
Colby Pharmaceutical’s most recent deal was a Corporate Asset Purchase with MannKind (Clinical Program Rights) for . The deal was made on 13-Nov-2012.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| MannKind (Clinical Program Rights) | 13-Nov-2012 | Corporate Asset Purchase | Buildings and Property | ||
| Othera Pharmaceuticals | 19-Sep-2012 | Merger/Acquisition | Drug Discovery | ||
| Juvaris BioTherapeutics | Merger/Acquisition | Drug Discovery |
Colby Pharmaceutical FAQs
-
When was Colby Pharmaceutical founded?
Colby Pharmaceutical was founded in 2004.
-
Where is Colby Pharmaceutical headquartered?
Colby Pharmaceutical is headquartered in Belvedere Tiburon, CA.
-
What is the size of Colby Pharmaceutical?
Colby Pharmaceutical has 4 total employees.
-
What industry is Colby Pharmaceutical in?
Colby Pharmaceutical’s primary industry is Drug Discovery.
-
Is Colby Pharmaceutical a private or public company?
Colby Pharmaceutical is a Private company.
-
What is Colby Pharmaceutical’s current revenue?
The current revenue for Colby Pharmaceutical is .
-
Who are Colby Pharmaceutical’s investors?
U.S. Department of Health and Human Services has invested in Colby Pharmaceutical.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
